HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Despite progress, ‘huge gap’ remains in understanding, application of minimal residual disease
• Prospective data needed to address knowledge gap in adjuvant therapy for upper tract urothelial carcinoma Petros Grivas, MD, PhD; Nima Almassi, MD
• Addition of pertuzumab to adjuvant regimen reduces recurrence risk in HER-2–positive breast cancer
• Barbara Ann Karmanos Cancer Institute appoints associate director
• Better physician–patient communication needed about costs of cancer care
• FDA grants priority review to enasidenib for IDH2–mutant AML
• Intratumoral therapy increases response to checkpoint inhibitor for melanoma
• Johns Hopkins names clinical director of medical oncology
• Juno Therapeutics halts development of JCAR015 for ALL
• Moffitt Cancer Center names gynecologic oncology program chair
• Oncology Nursing Society to present excellence award
• Psychologist joins Fox Chase Cancer Center
• Roswell Park official receives diversity leadership award
• Sapacitabine fails to improve OS in elderly patients with AML
• Strategies needed to improve childhood cancer survivors’ adherence to long-term follow-up
• Wistar Institute scientist receives grant for metastatic breast cancer research
• Peter C. Nowell, MD (1928-2016): Loss of an icon and iconoclast Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Xermelo for carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors
• FDA grants fast track designation to CMD-003 for lymphoma, posttransplant lymphoproliferative disease
• FDA grants priority review to avelumab for urothelial carcinoma
• FDA updates safety alert on breast implant–associated anaplastic large cell lymphoma, reports 9 deaths
• Adjuvant chemotherapy improves OS in upper tract urothelial carcinoma
• Antiangiogenic treatments prolong OS in glioblastoma subgroup
• Brachytherapy underused in treatment of locally advanced cervical cancer
• Lack of patient knowledge may contribute to overuse of contralateral prophylactic mastectomy
• Limited radiation exposure preserves intellectual functioning in some children with medulloblastoma
• Lower radiation doses have decreased incidence of second malignancies in childhood cancer survivors
• Lung cancer screening rates remain low among current, former smokers
• MET overexpression, amplification linked to worse prognosis for gastroesophageal adenocarcinoma
• Tailored dose-dense therapy fails to improve RFS in early breast cancer
• Testosterone treatment increases hemoglobin levels, improves anemia in older men
• Challenges remain in determining appropriate sequence of immunotherapy, BRAF/MEK inhibition
• Circulating tumor cell test can detect lung cancer recurrence before CT
• Dabrafenib plus trametinib demonstrates long-term tolerability in BRAF V600–mutated melanoma
• Hedgehog inhibitors ‘game changers’ for advanced basal cell carcinoma
• HIPEC well tolerated in gastric carcinomas
• In-house specialty pharmacy reduces medical errors, wait time
• Molecular data improves prediction of colorectal cancer recurrence
• NCI–designated cancer center websites lack sufficient information about breast cancer treatments
• New staging systems improve prediction of breast cancer survival
• Nivolumab, pembrolizumab exhibit different toxicity profiles as melanoma monotherapy
• Poor outcomes more common among minority populations with NSCLC
• Proton therapy shows promise for recurrent lung cancer
• Readmission rates after gynecologic surgery may not be a valid measurement of quality care
• Smartphone technology has ‘enormous potential’ to improve melanoma diagnosis
• Society outlines plan to address ‘crisis’ in gynecologic cancer trial access
• Strategies to detect immune-based biomarkers evolving for melanoma treatment
• Is minimal residual disease testing useful to direct patient care in multiple myeloma?